Cargando…
Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction
Pazopanib is an orally bioavailable tyrosine kinase inhibitor anticancer drug approved worldwide for the treatment of metastatic renal cell carcinoma and advanced soft tissue sarcoma. Here we report the case of a patient whose recurrent retroperitoneal soft tissue sarcoma showed a drastic reduction...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041368/ https://www.ncbi.nlm.nih.gov/pubmed/30003043 http://dx.doi.org/10.1016/j.eucr.2018.05.018 |
_version_ | 1783338980348002304 |
---|---|
author | Okubo, Kazuki Horiguchi, Akio Ito, Keiichi Asano, Tomohiko |
author_facet | Okubo, Kazuki Horiguchi, Akio Ito, Keiichi Asano, Tomohiko |
author_sort | Okubo, Kazuki |
collection | PubMed |
description | Pazopanib is an orally bioavailable tyrosine kinase inhibitor anticancer drug approved worldwide for the treatment of metastatic renal cell carcinoma and advanced soft tissue sarcoma. Here we report the case of a patient whose recurrent retroperitoneal soft tissue sarcoma showed a drastic reduction immediately after pazopanib administration accompanied by severe liver dysfunction. His liver function was restored conservatively by giving him hepatoprotectors and having him stop taking pazopanib. The recurrent tumor disappeared but by 4 months later had regrown. |
format | Online Article Text |
id | pubmed-6041368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-60413682018-07-12 Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction Okubo, Kazuki Horiguchi, Akio Ito, Keiichi Asano, Tomohiko Urol Case Rep Oncology Pazopanib is an orally bioavailable tyrosine kinase inhibitor anticancer drug approved worldwide for the treatment of metastatic renal cell carcinoma and advanced soft tissue sarcoma. Here we report the case of a patient whose recurrent retroperitoneal soft tissue sarcoma showed a drastic reduction immediately after pazopanib administration accompanied by severe liver dysfunction. His liver function was restored conservatively by giving him hepatoprotectors and having him stop taking pazopanib. The recurrent tumor disappeared but by 4 months later had regrown. Elsevier 2018-06-06 /pmc/articles/PMC6041368/ /pubmed/30003043 http://dx.doi.org/10.1016/j.eucr.2018.05.018 Text en © 2018 The Authors. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Oncology Okubo, Kazuki Horiguchi, Akio Ito, Keiichi Asano, Tomohiko Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction |
title | Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction |
title_full | Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction |
title_fullStr | Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction |
title_full_unstemmed | Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction |
title_short | Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction |
title_sort | recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041368/ https://www.ncbi.nlm.nih.gov/pubmed/30003043 http://dx.doi.org/10.1016/j.eucr.2018.05.018 |
work_keys_str_mv | AT okubokazuki recurrentretroperitonealsofttissuesarcomashowingdrasticreductionafterpazopanibadministrationaccompaniedbysevereliverdysfunction AT horiguchiakio recurrentretroperitonealsofttissuesarcomashowingdrasticreductionafterpazopanibadministrationaccompaniedbysevereliverdysfunction AT itokeiichi recurrentretroperitonealsofttissuesarcomashowingdrasticreductionafterpazopanibadministrationaccompaniedbysevereliverdysfunction AT asanotomohiko recurrentretroperitonealsofttissuesarcomashowingdrasticreductionafterpazopanibadministrationaccompaniedbysevereliverdysfunction |